ArticleMolecular therapy. Methods & clinical development2025
Comparative analysis of cell-specific promoters in AAV9-mediated gene therapy targeting the central nervous system.
Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Solute carrier membrane transporters: emerging targets in CNS disorders.Nature reviews. Drug discovery · 2026Review
- The delivery challenge of adeno-associated virus vector-based gene therapies for neurological diseases.Frontiers in neuroscience · 2026Review
- Gene replacement therapy for Piga GPI-anchor deficiency in the developing nervous system.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
We present a comprehensive toolkit of ubiquitous and cell-specific promoters for potential use in adeno-associated virus (AAV)9-mediated gene therapy for central nervous system (CNS) disorders, systematically evaluating biodistribution, cellular specificity, and peripheral targeting. While ubiquitous promoters, such as the cytomegalovirus early enhancer/chicken beta-actin (CAG) promoter, drive widespread expression, cell-specific promoters offer greater targeting precision. We introduce a novel, astrocyte-specific, truncated glial fibrillary acidic protein (GFAP) promoter, named gfaABCD1405 (gfa1405), which enhances astrocyte specificity while reducing size, improving utility for gene therapies requiring larger transgenes. gfa1405 demonstrated broader CNS expression than gfaABC(1)D, addressing previous limitations in AAV-mediated applications. The methyl CpG binding protein 2 promoter (p546) effectively targeted neurons, with strong expression in the neocortex and hippocampus, making it a promising candidate for neuronal disorders. Oligodendrocyte-specific promoters exhibited distinct patterns, with the myelin-associated glycoprotein (MAG) promoter driving expression in the corpus callosum, while the 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) promoter showed broader transduction, suggesting wider therapeutic applicability. This study establishes a promoter selection framework for AAV9-based gene therapy, enabling variable CNS cell-type targeting and optimizing therapeutic efficacy. By integrating comparative promoter analysis with gfa1405 development, we provide a practical collection for CNS-directed gene therapy, minimizing off-target effects and advancing treatment strategies for neurological disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.